Aspirin is widely used for cardiovascular disease prevention, but is associated with adverse gastrointestinal effects, which reduce the likelihood of treatment compliance. A new study shows that PPI co-therapy reduces gastrointestinal and cardiovascular events, and is cost-effective at generic price for treating patients who take aspirin for secondary cardiovascular disease prevention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Saini, S. D., Schoenfeld, P., Fendrick, A. M. & Scheiman, J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch. Intern. Med. 168, 1684–1690 (2008).
Saini, S. D., Fendrick, A. M. & Scheiman, J. M. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment. Pharmacol. Ther. 34, 243–251 (2011).
Baigent, C. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).
Chan, F. K. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352, 238–244 (2005).
Lai, K. C. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346, 2033–2038 (2002).
Sung, J. J. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med. 152, 1–9 (2010).
Melloni, C. et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am. J. Cardiol. 104, 175–181 (2009).
Bhatt, D. L. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118, 1894–1909 (2008).
Pant, C., Madonia, P. & Minocha, A. Does PPI therapy predispose to Clostridium difficile infection? Nat. Rev. Gastroenterol. Hepatol. 6, 555–557 (2009).
Earnshaw, S. R., Scheiman, J., Fendrick, A. M., McDade, C. & Pignone, M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch. Intern. Med. 171, 218–225 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F. K. L. Chan has received paid lecture fees from Pfizer, Takeda and AstraZeneca. S.C Ng has received paid lecture fees from Ferring.
Rights and permissions
About this article
Cite this article
Ng, S., Chan, F. PPI plus aspirin for secondary cardiovascular disease prevention. Nat Rev Gastroenterol Hepatol 8, 543–545 (2011). https://doi.org/10.1038/nrgastro.2011.164
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.164
